首页> 外文期刊>Transplantation Proceedings >Minimization of anti-hepatitis B surface antigen immunoglobulins for prophylaxis of hepatitis B viral recurrence in the first month after liver transplantation: The meaning of HBsAg quantitative level at the time of transplant
【24h】

Minimization of anti-hepatitis B surface antigen immunoglobulins for prophylaxis of hepatitis B viral recurrence in the first month after liver transplantation: The meaning of HBsAg quantitative level at the time of transplant

机译:最大限度地减少抗乙肝表面抗原免疫球蛋白预防肝移植后第一个月乙型肝炎病毒复发的可能性:移植时HBsAg定量水平的意义

获取原文
获取原文并翻译 | 示例
           

摘要

Background Hepatitis B virus recurrence after liver transplantation (LT) has practically disappeared with a prophylaxis combining anti-hepatitis B surface antigen Immunoglobulins (HBIg) and antiviral drugs. Recently, cost-saving requirements pushed us to move from a fixed schedule of 50,000 IU intravenous HBIg in the first month after LT to an "on demand" administration guided by close monitoring of HBV surface antigen (HBsAg) and anti-HBV surface Antigen antibody (HBsAb) with a serological target of HBsAg negative and HBsAb >300 mIU/mL. In this context, we investigated the meaning of HBsAg quantitative determination at LT in predicting the need of HBIg in the first month after LT.Methods From February 2012 to July 2013, we performed 35 LTs in HBsAg-positive patients, 18 of whom had hepatitis Delta virus coinfection (Delta-positive). Anti-HBV prophylaxis was based on nucleos(t)ide analogues from day 1 post-LT and intravenous HBIg (10,000 IU intraoperatively and, in the following days, 5,000 IU and 2,500 IU pulses to reach and maintain the serological target).Results The HBsAg quantitative level at LT was significantly higher in Delta-positive recipients. Complete negativization of HBsAg and HBsAb serum level >300 mIU/mL was achieved on day 3 in Delta-positive and on day 2 in Delta-negative. A positive linear correlation between HBsAg quantitative level at LT and HBIg administered in the first month after LT was observed (RHO =.788), with a total of 32,500 IU HBIg used in HDV-positive and 22,000 IU in HDV-negative recipients (P =.0016). Compared to the old schedule, we saved a median of 14,750 IU in HDV-positive and 28,000 IU in Delta-negative. No HBV recurrence was observed in a median follow-up of 10.5 months.Conclusions Delta-positive patients need higher doses of HBIg to reach the serological target after LT because they have greater HBsAg quantitative levels at LT. In future studies, pre-LT HBsAg quantitative determination will be helpful to predict the actual need of HBIg early after LT.
机译:背景技术结合抗乙型肝炎表面抗原免疫球蛋白(HBIg)和抗病毒药物的预防措施,使肝移植(LT)后的乙型肝炎病毒复发几乎消失了。最近,出于节省成本的要求,我们从LT术后第一个月的50,000 IU静脉内HBIg固定时间表转为通过密切监测HBV表面抗原(HBsAg)和抗HBV表面抗原抗体指导的“按需”给药(HBsAb),血清学指标为HBsAg阴性,且HBsAb> 300 mIU / mL。在此背景下,我们调查了在LT后第一个月中HBsAg定量测定对预测HBIg需求的意义。方法从2012年2月至2013年7月,我们对HBsAg阳性患者进行了35次LT,其中18例患有肝炎Delta病毒共感染(Delta阳性)。抗HBV的预防是基于LT后第1天和静脉注射HBIg(手术中10,000 IU,随后数天5,000 IU和2500 IU脉冲达到和维持血清学指标)的核苷酸(t)ide类似物。 Delta阳性接受者中LT的HBsAg定量水平显着更高。在Delta阳性的第3天和Delta阴性的第2天,HBsAg和HBsAb血清水平> 300 mIU / mL的完全阴性。观察到LT的HBsAg定量水平与LT后第一个月施用的HBIg之间呈线性正相关(RHO = .788),HDV阳性接受者共32,500 IU HBIg,HDV阴性接受者共22,000 IU(P = .0016)。与旧计划相比,HDV阳性的患者中位数为14750 IU,三角洲阴性的患者中位数为28000 IU。中位随访10.5个月未观察到HBV复发。结论Delta阳性患者在LT后需要更高剂量的HBIg才能达到血清学指标,因为他们在LT时的HBsAg定量水平更高。在未来的研究中,LT前的HBsAg定量测定将有助于预测LT后早期HBIg的实际需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号